Russia's opposition leader Alexei Navalny was detained at a Moscow airport after returning from Germany on Sunday. (Jan. 17)
Russia's opposition leader Alexei Navalny was detained at a Moscow airport after returning from Germany on Sunday. (Jan. 17)
German automaker Volkswagen said Friday it made a better than expected profit of 8.8 billion euros ($10.7 billion) after tax in 2020 despite the disruption from the pandemic. The company said the rapid recovery of China, its largest single market, helped the bottom line, as did resilient demand for luxury autos despite the pandemic. It tripled its sales of electric vehicles to 422,000 ahead of stricter European Union limits on emissions of carbon dioxide, the primary greenhouse gas blamed for global warming.
CONSTI PLC Managers Transactions on 26 February 2021 at 3.45 p.m. Consti Oyj - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Lähteinen, PirkkaPosition: Other senior managerIssuer: Consti PlcLEI: 743700JMXCC11CRJCS71 Notification type: INITIAL NOTIFICATIONReference number: 743700JMXCC11CRJCS71_20210226134937_5____________________________________________ Transaction date: 2021-02-25Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000178256Nature of the transaction: DISPOSAL Transaction details(1): Volume: 193 Unit price: 12.8 EUR Aggregated transactions(1): Volume: 193 Volume weighted average price: 12.8 EUR____________________________________________ Transaction date: 2021-02-26Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000178256Nature of the transaction: DISPOSAL Transaction details(1): Volume: 900 Unit price: 12.65 EUR(2): Volume: 800 Unit price: 12.75 EUR(3): Volume: 340 Unit price: 12.8 EUR Aggregated transactions(3): Volume: 2,040 Volume weighted average price: 12.71422 EUR CONSTI PLC Further information:Joni Sorsanen, CFO, Consti Plc, Tel. +358 50 443 3045 Distribution:Nasdaq Helsinki Ltd.Major mediawww.consti.fi Consti is a leading Finnish company concentrating on renovation and technical services. Consti offers comprehensive renovation and building technology services and selected new construction services to housing companies, corporations, investors and the public sector in Finland’s growth centres. Company has four business areas: Housing Companies, Corporations, Public Sector and Building Technology. In 2020, Consti Group’s net sales amounted to 275 million euro. It employs approximately 1000 professionals in renovation construction and building technology. Consti Plc is listed on Nasdaq Helsinki. The trading code is CONSTI. www.consti.fi
Ibere Pharmaceuticals (the "Company") announced today that it priced its upsized initial public offering of 12,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange ("NYSE") and will begin trading today, Friday, February 26, 2021, under the ticker symbol "IBERU". Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols "IBER" and "IBERW," respectively.
TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 01.202126.02.2021 Tresu Investment Holding A/S today publishes the Q4 2020 Interim Report and presentation of the financial results. TRESU Group is pleased to invite you to the financial results call, which is being held Tuesday, 2 March 2021, at 2pm CET. The Interim Report will be presented by Heidi Thousgaard Jørgensen, CEO. After the presentations there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. Click this link to register for the conference Heidi Thousgaard JørgensenCEO Further questions can be directed to: Heidi Thousgaard Jørgensen, CEO, Phone +45 2341 5085 Attachments Tresu Investment Holding – Q4 2020 Interim Report Tresu Investment Holding – Q4 2020 presentation
The Europe broth market is expected to grow from US$ 2,161. 49 million in 2019 to US$ 2,974. 33 million by 2027; it is estimated to grow at a CAGR of 4. 4% from 2020 to 2027. The Europe broth market is anticipated to account for a remarkable share of the global broth market during the forecast period.New York, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Broth Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type, Sales Channel, and Nature (Organic and Conventional" - https://www.reportlinker.com/p06004155/?utm_source=GNW The expansion of the retail industry along with high consumer reliability drives the growth of the Europe broth market.The retail foot traffic in both mall stores and stand-alone stores has been reduced in the past few years, and it is likely to continue during the forecast period.Amazon and other online retail companies hold a massive share in a slew of retail categories.Brands are now able to sell their products directly to consumers.Customer relationships are also now becoming digital-centric as consumers spend, on average, almost six hours on digital media daily.Digital channels are becoming the primary source for customers to purchase products, thus the retail market is growing. Although the e-commerce sector is growing rapidly across the region, physical stores are expected to remain an important part of customers’ shopping experience in the coming years.In terms of product type, the bone broth segment led the Europe broth market in 2019.Bone broth is a soup that is made by using bone and bone cartilage of chicken or beef.The demand for bone broth is increasing due to its versatile nutritional composition and high protein content.This type of broth offers various health benefits such as weight loss, joint pain relief, skin wrinkling and aging protection, and appetite reduction.The bone broth products also contain the highest amount of minerals—such as calcium and magnesium—than other animal protein-based products, giving a competitive edge over other animal protein sources resulting in growing demand. Thus, the rising demand for healthy food and beverage products drives the growth of the bone broth market in Europe.Bare Bone Broth, Del Monte Foods Inc., Paleo Broth Company, Campbell Soup Company, McCormick & Company Inc., Unilever, and Hain Celestial Group are a few players operating in the Europe broth market.At present, major countries in Europe are under lockdown due to the COVID-19 outbreak.Italy is the hardest-hit country in Europe as it recorded the highest number of COVID-19 cases.The country is experiencing an economic downturn due to the lack of revenue from various industries.Other European countries are also implementing drastic measures and travel restrictions by partially closing their borders.Also, isolation and social distancing measures have been imposed in the high-impact countries in the region. The lesser production of goods and commodities is hampering the growth of the Europe broth market as the demand for these products is witnessing decline since past couple of months.The overall Europe broth market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.The process also serves the purpose of obtaining an overview and forecast for the Europe broth market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.The participants typically associated with this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the Europe broth market.Read the full report: https://www.reportlinker.com/p06004155/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company"), a leading smart glass technology company that has developed and is commercializing patented thin-film solutions, today announced the appointments of Eddie Kovalik as President & Chief Operating Officer and Kai Sato as Co-President & Chief Marketing Officer.
The U.S. trade deficit in goods widened 0.7% to $83.7 billion in January, the Commerce Department said Friday.
If you are looking for a stock that can latch on to the 5G networks bandwagon, look no further than American Tower (NYSE: AMT). As of Sept. 30, 2020, the real estate investment trust (REIT) is the owner and operator of over 181,000 communication sites. American Tower derives a steady, predictable stream of rental income by leasing these properties to telecommunication companies.
The "Doors and Windows Market in North America - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference, being held March 15 – 17, 2021. A webcast of Celsion’s presentation will be pre-recorded and will be available on the Company’s website during the week before the conference. Institutional and other investors interested in meeting with Celsion during the conference should contact their Roth Capital Partners sales representative or LHA Investor Relations. Conference information is available at www.roth.com/oc2021virtual. About Celsion Corporation Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com. Celsion Investor ContactJeffrey W. ChurchExecutive Vice President and CFO609email@example.com LHA Investor RelationsKim Sutton Golodetz212firstname.lastname@example.org # # #
Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Lactose Free Dairy Products Market: Focus on Products (Milk, Cheese, Yogurt), Applications (Direct, Retail), and Country Level Analysis - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering. The lactose-free dairy products market is expected to reach $12.09 billionMarket growth is largely attributed to the adoption of dairy products, such as lactose free milk for regular consumption and lactose free yogurt as a snack item. The global dairy industry is witnessing continual growth in terms of production and availability of diverse dairy products across all major regions. Owing to the popularity of consumption benefits of dairy products, at least one dairy product is being consumed by an individual on a daily basis, globally. This has, in turn, enabled many consumers to detect lactose intolerance, which does not allow proper digestion of dairy products. According to global surveys in 2019, around 65-70% of the global population is expected to be lactose intolerant.Most of the consumers who face indigestion due to lactose intolerance do not notice the related symptoms or tend to ignore them. Many dairy consumers have also stopped the consumption of dairy products to avoid uneasiness. This is evident from the declining milk consumption levels globally.For instance, in the U.S., milk consumption has plummeted by over 40% from 1975 to 2019, with consumption of 247 pounds per capita in 1975 to 149 pounds per capita in 2019. This has given rise to the popularity of lactose free dairy products, which act as a solution to the growing lactose intolerance globally. Dairy products that are commonly used regularly are widely available in their lactose free variant. These include milk (both white milk and flavored milk), yogurt, cheese, and milk powder, among others. The most upcoming product categories under lactose free dairy products include ice creams and dietary supplements.Some of the most prominent players in the lactose free dairy products market are Valio Ltd., Arla Foods, Nestle S.A., Granarolo Group, Lactaid, and Dean Foods. The result of the emerging strategies and developments are already surging the market in the form of product launches. Moreover, the growing market of lactose free dairy products is further expected to increase the involvement of companies across different segments of the value chain. The majority of the companies preferred launching new products to offer the customers a wide variety to choose from, while the relatively less adoptive strategies comprised business expansions in new regions, thus increasing awareness about lactose free dairy products. For instance, in February 2020, Arla Foods set up a new dairy plant in Sweden to export lactose free dairy products to the U.K. This report is a meticulous compilation of research on more than 100 players in the lactose free dairy products ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 40 leading companies, market participants, and vendors. The report also profiles 15 leading companies across the lactose free dairy products supply chain. Key profiles include Valio Ltd., Arla Foods, Nestle S.A., Granarolo Group, Lactaid, and Dean Foods, among others. Key Questions Answered in this Report: What are the key drivers and challenges in the global lactose free dairy products market?How does the supply chain function in the global lactose free dairy products market?Which product type segment is expected to witness the maximum demand growth in the global lactose free dairy products market during 2020-2025?Which are the key application areas for which different lactose free dairy products may experience high demand during the forecast period, 2020-2025?Who are the key suppliers of different lactose free dairy products?What are the business and corporate strategies of market players involved in the global lactose free dairy products market?What are the key offerings of the prominent companies in the market for lactose free dairy products?Which regions and countries are leading in terms of consumption of global lactose free dairy products market, and which of them are expected to witness high demand growth during 2020-2025?What are the expected key consumer attributes in various regions for the period 2020-2025?What are the developments in the market landscape for lactose free dairy products manufacturers? Key Topics Covered: 1 Markets1.1 Industry Outlook1.1.1 Trends: Industry Dynamics Defining the Future Trends in Lactose-Free Dairy Products1.1.2 Supply Chain Analysis1.1.3 Industry Attractiveness1.1.4 Ecosystem/Ongoing Programs1.2 Business Dynamics1.2.1 Business Drivers188.8.131.52 Impact of Business Drivers184.108.40.206 Rise in Demand for Healthier Dairy Alternatives220.127.116.11 Growing Lactose Intolerant Population18.104.22.168 Rising Purchasing Power of Consumers1.2.2 Business Challenges22.214.171.124 Impact of Business Challenges126.96.36.199 Taste and Preferences of Consumers1.2.3 Business Strategies188.8.131.52 Product Developments184.108.40.206 Market Developments1.2.4 Corporate Strategies220.127.116.11 Mergers and Acquisitions, Partnerships, Joint Ventures, Collaborations, and Alliances1.2.5 Business Opportunities18.104.22.168 Impact of Business Opportunities22.214.171.124 Increasing Private Label Offerings126.96.36.199 Product Diversification in Lactose-Free Dairy Offerings1.2.6 Impact Analysis of Covid-192 Applications2.1 Lactose-Free Dairy Products Market - Distribution Channel2.1.1 Direct Distribution2.1.2 Retail Distribution2.2 Lactose-Free Dairy Products Market - Demand Analysis (By Distribution Channel)2.2.1 Direct Sales2.2.2 Retail Sales188.8.131.52 Supermarkets/Hypermarkets184.108.40.206 Small Retail Stores220.127.116.11 Online Sales18.104.22.168 Others (Convenience Stores, Specialty Stores, and Kiosks) 3 Products3.1 Lactose-Free Dairy Products Market - Products and Specifications3.1.1 Milk3.1.2 Cheese3.1.3 Yogurt3.1.4 Ice-Cream3.1.5 Others3.2 Lactose-Free Dairy Products Market - Demand Analysis (By Product)3.2.1 Demand Analysis (By Product), Value & Volume Data22.214.171.124 Milk126.96.36.199 Cheese188.8.131.52 Yogurt184.108.40.206 Ice-Cream220.127.116.11 Others3.3 Product Benchmarking: Growth Rate - Market Share Matrix3.3.1 Opportunity Matrix, by Region3.3.2 Opportunity Matrix, by Product Type3.4 Pricing Analysis 4 Regions4.1 Markets4.1.1 Competitive Benchmarking4.1.2 Key Manufacturers in North America4.1.3 Business Challenges4.1.4 Business Drivers4.2 Applications4.2.1 North America Lactose-Free Dairy Products Market (By Application), Value Data4.3 Products 5 Markets - Competitive Benchmarking & Company Profiles Almarai CompanyArla FoodsCentrale del Latte d'Italia S.p.A.Danone S.A.Dean FoodsGranarolo GroupHolland Dairy FoodsLactaidMurray Goulburn Co-operative Co. LimitedNestle S.A.Organic ValleyParmalat S.p.A.Savencia Fromage & DairySodiaal GroupValio Ltd. For more information about this report visit https://www.researchandmarkets.com/r/do2qfx CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
House expected to pass stimulus bill today, retail wage wars heat up, nursing home Covid-19 cases have dropped sharply, and other news to start your day.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19. PLC is the second hospital in Calgary to participate in the trial, joining University of Calgary Cumming School of Medicine at the Foothills Medical Centre that started enrolling patients last month. PLC enrolled its first patient into the study earlier this week. Patient enrollment is ongoing in the United States. Sites in Turkey continue to wait for permission from the Turkish Ministry of Health to expand enrollment there. “We welcome Peter Lougheed Centre into the study and expect to finish dosing in the trial in the coming weeks,” said Richard Muruve, CEO of Arch Biopartners. About the Phase II trial for LSALT Peptide The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in patients infected with SARS-CoV-2 (COVID-19). ARDS is the leading cause of death in COVID-infected patients. AKI has been observed in approximately 35% of patients admitted to hospital with COVID-19 and is also a leading cause of mortality.1 The composite primary endpoint of the Phase II trial reflects the severe effects often experienced by hospitalized COVID-19 patients and deemed appropriate for LSALT peptide’s novel mechanism of action in blocking consequential inflammation in the lungs, kidneys, and other organs. Additional information about the Phase II trial can be found at: https://clinicaltrials.gov/ct2/show/NCT04402957. The Phase II results will be used to design the Phase III program, including greater patient numbers to more fully evaluate efficacy and safety in COVID-19 patients. About COVID-19 COVID-19 is the disease caused by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. Severe complications from COVID-19 are in large part due to excessive host immune responses to the virus that result in progressive lung inflammation and acute respiratory distress syndrome that often requires mechanical ventilation and critical care1. Patients with severe COVID-19 also experience multiple organ dysfunction including acute kidney injury, liver dysfunction, cardiac failure, and blood abnormalities. Currently, no effective antiviral drug or specific treatment exists for SARS-CoV-2 infection. Treatment of severe COVID-19 has been primarily supportive, relying heavily on respiratory, infectious diseases, and critical care medicine. Survival rates and health care system capacity could both be improved with new treatments that prevent the severe manifestations of COVID-19, such as worsening lung inflammation (ARDS) and AKI experienced by patients infected with SARS-CoV-2.2 1 Hirsch JS et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 doi: https://doi.org/10.1016/j.kint.2020.05.006.2 J. S. Ayres, Sci. Adv 10.1126/sciadv.abc1518 (2020) About Arch Biopartners Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications. For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com. The Company has 61,362,302 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change. The science and medical contents of this release have been approved by the Company’s Chief Science Officer The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus) at this time Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release CONTACT: For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 firstname.lastname@example.org
Artificial intelligence affords investment specialists the ability to make autonomous assessment of market conditions, removed from the frailties of human decision making, argues a new white paper by Plotinus Asset Management. That capability, in turn, means that institutional investors are set to inject fresh strategies into their longstanding techniques.
The company had been in exclusive talks with L Catterton for the last several weeks.
Viatec announces their flagship product SmartPTO is now incentive eligible under the California Air Resources Board's Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project. The incentive project was launched to accelerate the adoption of cleaner, more-efficient trucks and buses. Viatec's SmartPTO allows bucket truck operators seeking an ePTO solution to begin their transition into using electricity as a fuel.
("Cineplex" or the "Company") (TSX: CGX) today announced that it has closed its previously announced private placement offering of $250 million aggregate principal amount of 7.5% senior secured second lien notes (the "Notes" ) due February 26, 2026 (the "Notes Offering").
It turns out that making a feature-length live action-animated hybrid movie about two characters who don't speak is hard, particularly when the human half makes no sense.
The world's financial leaders are expected on Friday to agree to continue their support measures for the global economy and look to boost the International Monetary Fund's resources so it can help poorer countries fight off the effects of the pandemic. Finance ministers and central bank governors of the world's top 20 economies, called the G20, held a video-conference on Friday and top of the agenda was the global response to the economic havoc wreaked by the coronavirus. German Finance Minister Olaf Scholz warned that recovery was taking longer than expected and it was too early to roll back support.
MercadoLibre (NASDAQ: MELI) and Alibaba (NYSE: BABA) are two of the world's largest e-commerce companies. MercadoLibre, founded in Argentina in 1999, is Latin America's leading e-commerce player with a presence in 18 countries. Alibaba launched the same year and has become China's top e-commerce and cloud services company.